Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
Clinically relevant animal models of mammary carcinogenesis are crucial for the development and evaluation of new breast cancer chemopreventive agents. The neu-induced retroviral rat mammary carcinogenesis model is based on the direct in situ transfer of the activated neu oncogene into the mammary epithelium using a replication-defective retroviral vector. The resulting mammary carcinomas in intact Wistar-Furth rats exhibit a mixed hormonal response in the same proportion as has been observed in women. In intact rats, approximately 50% of mammary carcinomas can be prevented by tamoxifen treatment. In ovariectomized animals, the mammary carcinomas are hormonally nonresponsive and cannot be prevented by tamoxifen. We evaluated the efficacy of retinoic X receptor-selective retinoids (rexinoids) in this novel model of mammary carcinogenesis. The rexinoids LG100268 and bexarotene (LG1069, Targretin) were highly efficacious in the prevention of neu-induced mammary carcinomas. Dietary LG100268 at 100 mg/kg diet decreased tumor multiplicity by 32% (P = 0.0114) in intact rats and 50% (P < 0.0001) in ovariectomized rats. Bexarotene treatment at a dose of 250 mg/kg diet was associated with reductions in tumor multiplicity of 84% (P < 0.0001) and 86% (P < 0.0001) in intact and ovariectomized animals, respectively. In addition to tumor multiplicity, proliferation and apoptosis were modulated by bexarotene treatment independently of estrogen signaling. The neu-induced retroviral rat mammary carcinogenesis model represents a valuable addition to existing rodent chemoprevention models. The model is useful for assessing the efficacy of chemopreventive agents, specifically those compounds that target hormonally nonresponsive tumors.
Woditschka
Stephan
S
McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University Avenue, Madison, WI 53706, USA.
Haag
Jill D
JD
Waller
Jordy L
JL
Monson
Dinelli M
DM
Hitt
Andrew A
AA
Brose
Heidi L
HL
Hu
Rong
R
Zheng
Yun
Y
Watson
Philip A
PA
Kim
Kwanghee
K
Lindstrom
Mary J
MJ
Mau
Bob
B
Steele
Vernon E
VE
Lubet
Ronald A
RA
Gould
Michael N
MN
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D000077610:Bexarotene; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D005260:Female; D018734:Genes, erbB-2; D005822:Genetic Vectors / Q000235:genetics; D008325:Mammary Neoplasms, Experimental / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D009539:Nicotinic Acids / Q000494:pharmacology; D051381:Rats; D011920:Rats, Inbred WF; D012190:Retroviridae / Q000235:genetics; D013629:Tamoxifen / Q000494:pharmacology; D013764:Tetrahydronaphthalenes / Q000494:pharmacology
D016588:Anticarcinogenic Agents; D009539:Nicotinic Acids; D013764:Tetrahydronaphthalenes; D013629:Tamoxifen; D000077610:Bexarotene; C095104:LG 100268